Clinical trial
Cetuximab in Neoadjuvant Treatment of Non-Resectable Colorectal Liver Metastases…
NCT00153998 · Technische Universität Dresden, Other · Completed
Key facts
| NCT number | NCT00153998 |
|---|---|
| Title | Cetuximab in Neoadjuvant Treatment of Non-Resectable Colorectal Liver Metastases (CELIM) |
| Official title | Open, Randomized, Multicenter, Randomized Phase II Trial Comparing the Combination of Cetuximab With Oxaliplatin/5-FU/FA Versus the Combination of Cetuximab With Irinotecan/5-FU/FA as Neoadjuvant Treatment in Patients With Non-Resectable Colorectal Liver Metastases |
| Lead sponsor | Technische Universität Dresden, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Colorectal Cancer, Liver Metastases |
| Intervention type | Drug, Procedure |
| Interventions | Cetuximab, Liver resection, Cetuximab and FOLFIRI, Cetuximab and FOLFOX |
| Enrollment | 135 |
| Start date | Nov 1, 2004 |
| Primary completion | Mar 1, 2008 |
| First posted | Sep 12, 2005 |
| Last update posted | Feb 27, 2009 |
| Countries | Austria, Germany |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: